Brian Lian
President, CEO & DirectorDr. Brian Lian, Ph.D., served as Director at Apricus Biosciences, Inc. He has been the Chief Executive Officer and President at Viking Therapeutics, Inc. since September 24, 2012. Dr. Lian had been an Independent Director of Seelos Therapeutics, Inc. since January 24, 2019 until 2025. He served as Managing Director and Senior Research Analyst at SunTrust Robinson Humphrey, Inc., Research Division from 2012 to 2013. Prior to SunTrust Robinson Humphrey, he was Managing Director and Senior Research Analyst at Global Hunter Securities, an investment bank, from 2011 to 2012. He served as a Managing Director and Senior Biotechnology Analyst of Healthcare Group of Seaport Global Securities LLC, Research Division. He was Senior Healthcare Analyst at The Agave Group, LLC, from 2008 to 2011. He served as an Equity Analyst of BNP Paribas Fortis, Research Division. Prior to The Agave Group, he was an Executive Director and Senior Biotechnology Analyst at CIBC World Markets, from 2006 to 2008. He served as Research Analyst at CIBC World Markets Corp., American Research Division. He served as Senior Biotechnology Analyst at Oppenheimer & Co. Inc., Research Division. He served as Senior Research Analyst at CIBC World Markets Inc., Research Division. He served as Senior Research Analyst at Fortis Securities Inc., Research Division. He served as Managing Director of Healthcare Research at Meridian Equity Partners, Inc., Research Division and Meridian Equity Partners, Inc. He served as Research Scientist at Amgen Inc. He joined Meridian Equity Partners, Inc. from The Agave Group LLC, a New York-based research boutique and has experience covering the healthcare sector. From 2003 to 2008, he covered biotechnology and specialty pharmaceutical companies. He served as Senior Research Analyst for Biotechnology at Fortis Bank. In 2008, he founded The Agave Group, a healthcare research platform to serve portfolio managers, analysts, traders and corporate clients. He was a Research Scientist at Microcide Pharmaceuticals, where he worked in collaboration with Pfizer to identify novel classes of antibiotics. He worked at The Agave Group LLC. He served as Interim Chairman of Viking Therapeutics, Inc. until June 4, 2015. He was Executive Director and Senior Research Analyst at CIBC Capital Markets, Research Division. He has been a Director at Viking Therapeutics, Inc. since September 24, 2014. He served as an Executive Director at Oppenheimer & Co. Inc., Research Division and at CIBC World Markets Inc., Research Division. He co-authored research in organic chemistry, medicinal chemistry, biochemistry and chemical physics and contributed to texts in organic and advanced organic chemistry. Dr. Lian received MS and Ph.D. in Organic Chemistry from The University of Michigan, an M.B.A. in Finance and Accounting from Indiana University and a B.A. in Chemistry from Whitman College.
Positions
- Company NameViking Therapeutics, Inc.Stock CodeVKTXPositionPresident, CEO & DirectorColleagues
- LMLawson MacArtneyIndependent Chairman
- GSGregory S. ZanteChief Financial Officer
- MMMichael MorneauVice President of Finance & Administration
- KMKatherine MercierVice President of Quality & Compliance
- KJKenneth J. HermanSenior Vice President of Commercial, Marketing & Sales
- JMJ. Matthew SingletonIndependent Director
- CACharles A. RowlandIndependent Director
- SKSarah Kathryn RouanIndependent Director
